Jaguar Health Inc. (NASDAQ:JAGX) Provides Updates On Its Commercial, Educational And Product Development

0
194

Jaguar Health Inc. (NASDAQ:JAGX) has made public its latest updates. The commercial stage natural-products pharmaceuticals company confirms having merged with Napo Pharmaceuticals. The merger has resulted in the acquiring of Napo’s Mytesi, which is a first-in-class, FDA-approved anti-secretory human prescription drug product. However, Napo will still be part and parcel of streamlining and expanding nationwide patient access to Mytesi. This comes as a result of a signed agreement between Napo and pharmacy services provider Transition Patient Services (TPS).

Jaguar’s and Napo’s paramount focus is on driving Mytesi sales

According to Jaguar’s President and CEO, Lisa Conte, Mytesi has the potential and the metrics to be successful. It has the ability to offer first-in-class gastrointestinal supportive care in the HIV community. Conte, adds that the company is able to exhibit the prospects of long-term sales growth.

“We currently anticipate that Mytesi gross sales for the period of January 1, 2017, through March 31, 2018, will total approximately $3.2 million”, says Conte. The merger by the duo is also expected to play a significant role in reducing barriers to acquiring and accessing Mytesi.

On the other hand, TPS will offer a nationwide pilot program for Mytesi in an effort to ensure that the users are receiving their prescriptions on time and at pocket-friendly prices. The pharmacy services provider has the licensing in all 50 states and is dedicated to enhancing patient outcomes.

The two companies have bigger plans for 2018

Apparently, Mytesi is the only U.S. FDA-approved treatment for noninfectious diarrhea in adults living with HIV/AIDS. Apparently, the two companies are not only looking at Mytesi. They have other plans outlined, which include extensive sales and marketing programs. They will also be engaging in advertising and promotional activities as well as increased focus on patient empowerment.

Napo has 29 healthcare practitioners (HCPs), 3,500 high-volume ART prescribers, ten patient advocates and 1,500 gastroenterologists. Among Napo’s nine highly trained Mytesi sales representatives six of them are former employees of drugmaker Bristol-Myers Squibb.  Nonetheless, every one of them has extensive experience in drug sales.

LEAVE A REPLY

Please enter your comment!
Please enter your name here